JAB-BX102 Monotherapy and Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors

Inclusion Criteria:

• Must be able to provide an archived tumor sample

• Must have histologically or cytologically confirmed metastatic or locally advancedsolid tumor

• Must be refractory to or become intolerant of existing therapy(ies) known to provideclinical benefit for their condition, or patient has no access to SOC treatment.

• Must have at least 1 measurable lesion per RECIST v1.1

• Must have adequate organ functions

Exclusion Criteria:

• Has central nervous system(CNS) metastases or carcinomatous meningitis, except ifCNS metastases treated and no evidence of radiographic progression or hemorrhage forat least 28 days

• Active infection requiring systemic treatment within 7 days

• Active hepatitis C virus(HBV), hepatitis C virus(HCV), or HIV

• Any severe and/or uncontrolled medical conditions

• Left ventricular ejection fraction(LVEF) ≤50% assessed by echocardiogram (ECHO) ormultigated acquisition scan (MUGA)

• QTcF(Corrected QT interval - Fredericia formula) interval >470 msec

• Experiencing unresolved CTCAE 5.0 Grade >1 toxicities